RxDoctor Payments Data

Deanna Mendoza, APRN

Family · Hutto, TXNPI 1407368772

Payments from drug & device makers

$1,649in general payments, 2019–2025

Across 64 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$415
  • Novartis$294
  • Novo Nordisk$245
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$114
  • AstraZeneca$100
  • Abbott$73
  • plus $409 from 11 others

What the payments were for

  • Food & beverage$1,62899%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,649 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$33,968
Medicare patients
153
Services billed
711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$18,403
SynthroidLevothyroxine Sodium14$812
Albuterol Sulfate HfaAlbuterol Sulfate21$685
Levothyroxine Sodium60$572
Omeprazole37$460
Atorvastatin Calcium54$443
Gabapentin20$408
Amlodipine Besylate56$327
Lisinopril39$300
Metoprolol Succinate17$269
Pioglitazone Hcl22$266
Losartan Potassium33$262
Azelastine Hcl16$222
Fluticasone Propionate18$201
Baclofen13$197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$245$18,40315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.

Other family in Hutto

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →